MNG1244
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.387
- E2F_TARGETS+0.386
- CHOLESTEROL_HOMEOSTASIS+0.370
- ESTROGEN_RESPONSE_EARLY+0.361
- TNFA_SIGNALING_VIA_NFKB+0.343
- APICAL_SURFACE+0.336
- ESTROGEN_RESPONSE_LATE+0.335
- G2M_CHECKPOINT+0.323
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.317
- MYOGENESIS+0.311
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.306
- MYC_TARGETS_V2-0.256
- INTERFERON_GAMMA_RESPONSE-0.196
- IL6_JAK_STAT3_SIGNALING-0.167
- INFLAMMATORY_RESPONSE-0.153
- PROTEIN_SECRETION-0.144
- WNT_BETA_CATENIN_SIGNALING-0.144
- OXIDATIVE_PHOSPHORYLATION-0.136
- MYC_TARGETS_V1-0.134
- UNFOLDED_PROTEIN_RESPONSE-0.073
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG223 | — | — | 0.810 |
| 2 | s0112232 | — | — | 0.754 |
| 3 | TCGA-B6-A0RI-01A-11R-A056-07 | — | B | 0.730 |
| 4 | SRR8518205 | — | E | 0.704 |
| 5 | TCGA-CV-6961-01A-21R-1915-07 | — | — | 0.690 |
| 6 | MBCProject_0006_T3_RNA | — | A | 0.684 |
| 7 | MNG1272 | — | — | 0.679 |
| 8 | R211 | — | — | 0.669 |
| 9 | TCGA-E9-A1N6-01A-11R-A144-07 | — | C | 0.667 |
| 10 | TCGA-A1-A0SJ-01A-11R-A084-07 | — | B | 0.667 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.387 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.386 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.361 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.343 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.336 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.335 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.323 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.317 | Inavolisib | — uncovered |
| MYOGENESIS | 0.311 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.294 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.268 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.233 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.204 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.196 | Idelalisib | — uncovered |
| HYPOXIA | 0.194 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.183 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.174 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.171 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.167 | Inavolisib | — uncovered |